# Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder

> **NCT00191022** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 185 (—)

## Conditions studied

- Social Phobia

## Interventions

- **DRUG:** LY686017
- **DRUG:** paroxetine
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00191022
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** —
- **Final completion:** 2007-01
- **Target enrollment:** 185 (—)
- **Last updated:** 2007-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00191022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00191022, "Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT00191022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*